ReviewMolecular diversity2016
Calixdrugs: calixarene-based clusters of established therapeutic drug agents.
Review in Molecular diversity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Syntheses and biological activities of calix[4]resorcinarene derivatives modified by sulfonic acid and sulfonamides.RSC advances · 2024Article
- Membrane-Active Antibacterial Agents Based on Calix[4]arene Derivatives: Synthesis and Biological Evaluation.Frontiers in chemistry · 2022Article
- Synthesis of calixresorcarenes using magnetic poly triazine-benzene sulfonamide-SORSC advances · 2021Article
- Calix[4]API-s: fully functionalized calix[4]arene-based facial active pharmaceutical ingredients.Molecular diversity · 2021Review
- Macrocycles and Supramolecules as Antioxidants: Excellent Scaffolds for Development of Potential Therapeutic Agents.Antioxidants (Basel, Switzerland) · 2020Review
- Calixarbutin: A Novel Calixarene-based Potential Water-soluble Anti-tyrosinase Agent with High Anti-melanoma Activity.Iranian journal of pharmaceutical research : IJPR · 2020Article
- Highly functionalized calix[4]arenesRSC advances · 2019Review
- Antiradical and Antioxidative Activity of Azocalix[4]arene Derivatives: Combined Experimental and Theoretical Study.Molecules (Basel, Switzerland) · 2019Article
- Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Calixapap: Calixarene-based Cluster of Acetaminophen as a Novel Antiradical Agent.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Winged-Cone Conformation in Hexa-ACS omega · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calixdrugs are calix[4]arene-based clusters (chaliced shapes) of established therapeutic drugs (e.g., penicillin, cephalosporin, tyrosol, and carboplatin) that are innovatively named calixpenam, calixcephem, calixtyrosol, and calixplatin, respectively. Going over the structures of cluster compounds, the calixarene scaffold lies at the heart of the structure (chaliced shape of drug), and it is an integral part of the cluster. In fact, the monomer drugs contribute as 1/4 of the corresponding cluster. In addition, probably because of the multivalency, spatial preorganization, and synergistic effect of four impacted drug units in the structures of calixdrugs, they are more effective in interactions with the target sites over their corresponding monomers.
Indexed as
Identifiers
27017350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.